American Thoracic Society - Sanofi Investor Call

Strong immunology pipeline with 12 novel molecules to build and expand in leading franchise AD Dermatology CSU Psoriasis Respiratory Asthma Orals rilzabrutinib (BTKI) IRAK4 degrader rilzabrutinib (BTKI) Oral TNF inhibitor rilzabrutinib (BTKI) Injectables DupixentⓇ amlitelimab (anti-OX40L) DupixentⓇ DupixentⓇ amlitelimab (anti-OX40L) Anti-IL-13/TSLP NanobodyⓇ VHH DupixentⓇ itepekimab (anti-IL-33) DupixentⓇ DupixentⓇ COPD EoE EG Gastroenterology UC eclitasertib (RIPK1i) non-beta IL-2 (SynthorinⓇ compound) Autoimmune Lupus eclitasertib (RIPK1i) frexalimab (anti-CD40L) Anti-CD38 mAb Next Generation. DupixentⓇ sanofi Dupixent® is jointly developed and co-commercialized with Regeneron. Itepekimab is being developed in collaboration with Regeneron. DupixentⓇ is under investigation in CSU, COPD, EG and UC and not yet approved by any regulatory agency to treat these indications. All other agents described above are in clinical development and the safety/efficacy has not been established nor reviewed by any regulatory agency. 7 ATS Investor Call

View entire presentation